How to Buy Spyre Therapeutics Stock
Spyre Therapeutics Inc
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD).
Spyre Therapeutics stock last closed at $96.56, down 2.43% from the previous day, and has increased 298.02% in one year. It has overperformed other stocks in the Biotechnology industry by 3.64 percentage points. Spyre Therapeutics stock is currently +356.66% from its 52-week low of $21.15, and -12.36% from its 52-week high of $110.18.
At the moment, there are 88.17M SYRE shares outstanding. The market capitalization of SYRE is $8.51B. In the last 24 hours, 658,000 SYRE shares were traded.
How to Buy Spyre Therapeutics Stock
Wondering how to invest in Spyre Therapeutics stock? Here's how.
- Choose where to buy Spyre Therapeutics stock: You need to decide on a stock brokerage, but don't worry - we've sifted through dozens of stock brokerages and apps to help you figure out where to buy Spyre Therapeutics stock.
- Open your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
- Fund your brokerage account: Pick your method of payment and add your info.
- Analyze Spyre Therapeutics stock: The Spyre Therapeutics ticker symbol is SYRE. Is Spyre Therapeutics stock a good investment? Should you buy shares of SYRE? How do SYRE's underlying business fundamentals look? Do top analysts think Spyre Therapeutics is a good buy? Why has SYRE's stock price moved recently? (Hint: Our stock market research tools can help you decide if SYRE is a good stock to buy).
- Make your SYRE buy order: Decide if you will purchase SYRE shares at the current market price or use a limit order to buy SYRE shares at a given price.
- Get notifications regarding your SYRE position: Create a watchlist to important updates regarding your new investment in Spyre Therapeutics shares.
Step 1: Choose where to buy Spyre Therapeutics stock
You will need an online brokerage account to access the NASDAQ market and buy SYRE shares.
Our favorite brokerage: eToro
Based on our research, eToro is the best online stock brokerage. Here's why:
- You can invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to global markets: From Tech to Healthcare, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading exchanges.
- Social investing: eToro has a community of more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by opening an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Open your brokerage account
Now that you've chosen the best brokerage, you'll need to fill out some personal info so you are able to buy SYRE today.
How to Create a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal details to create a new brokerage account.
- Send your application by clicking the "Create Account" button. Get started with eToro today
Step 3: Fund your brokerage account
Now that you have filled out your info on the best free stock trading app, you need to deposit funds:
Watch the tutorial below to see the process of transferring funds into your brokerage account.
Step 4: Analyze Spyre Therapeutics stock
Once you have decided on the best place to buy Spyre Therapeutics stock, it's crucial to research their stock before you buy, so you truly understand the risk as well as the opportunity.
Spyre Therapeutics stock at a glance
SYRE Due Diligence Score
WallStreetZen was built to help everyday investors perform more in-depth fundamental analysis quickly.
You can view all of the due diligence checks on SYRE's stock page.
Is SYRE stock overvalued?
Investors use a variety of different financial metrics, analyses, models, and charts to gauge SYRE's fair value.
Using relative valuations measures:
- SYRE could be overvalued based on its P/B ratio of 7.73x, relative to Biotechnology industry P/B ratio of 5.17x
You can access additional valuation research on SYRE's stock here.
A look at SYRE Cashflows and Balance Sheet
Pros:
- Total SYRE debt is lower than 5 years ago, relative to shareholder equity.
- SYRE has $1.15B in cash and short term investments. This is sufficient to cover its annual cash burn of $208.94M.
- SYRE has cash burn of 208944000. It has sufficient cash and short-term investments to cover this for at least one year.
- There are more short-term assets than long-term liabilities on the SYRE balance sheet.
- SYRE has a low debt to equity ratio of 0.07.
- There are more short-term assets than short-term liabilities on the SYRE balance sheet.
Is Spyre Therapeutics stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 11 sell side analysts who give forecasts on SYRE, the consensus analyst rating on Spyre Therapeutics is a Strong Buy
It's important to keep in mind that analyst forecasts are not recommendations, nor are they investment advice.
Most Recent SYRE Analyst Ratings
Yanan Zhu, a top 22% analyst from Wells Fargo maintains SYRE with a strong buy rating and raises their SYRE price target from $90.00 to $115.00, on Aug 5, 2026.
Yatin Suneja, a top 3% analyst from Guggenheim maintains SYRE with a strong buy rating and raises their SYRE price target from $115.00 to $130.00, on Aug 5, 2026.
Guggenheim's Yatin Suneja raised their price target on Spyre Therapeutics (NASDAQ: SYRE) by 13% from $115 to $130 on 2026/08/05. The analyst maintained their Strong Buy rating on the stock.
Spyre Therapeutics reported its Q2 2026 earnings.
Raising their price target, Suneja expressed the view that the company is "best positioned to pioneer longer-acting mAb therapeutics in IBD."
Earnings Report
For Q2 2026, Spyre Therapeutics reported:
- EPS of $0.36 cents, which beat the Zacks Consensus Estimate of $(71) and Q2 2025's $(0.49).
- Revenue of $0.00.
Management did not provide financial guidance in its press release.
CEO Cameron Turtle, DPhil, commented: “Following encouraging Phase 2 results from both SPY001 and SPY002, as well as competitor results validating the promise of combination therapy, the case for our approach in IBD has strengthened considerably.
"We believe our three investigational combinations have the potential to deliver efficacy, safety, and convenience beyond what is achievable with today’s therapies.
“Beyond IBD, we are approaching a pivotal milestone with placebo-controlled Phase 2 proof-of-concept data for SPY072, an anti-TL1A monotherapy, in rheumatoid arthritis expected next month, representing a key opportunity to demonstrate the broader utility of this mechanism.
"If successful, we look forward to initiating pivotal development of SPY072 next year, while also exploring combination approaches outside IBD.”
Andy Chen, a top 9% analyst from Wolfe Research downgrades SYRE to a hold rating, on Jul 28, 2026.
Joseph Catanzaro, a top 18% analyst from Mizuho maintains SYRE with a buy rating and raises their SYRE price target from $84.00 to $120.00, on Jul 13, 2026.
Samantha Semenkow, a bottom 10% analyst from Citigroup maintains SYRE with a strong buy rating and raises their SYRE price target from $64.00 to $97.00, on May 6, 2026.
You can dive deeper into what analysts are forecasting on the Spyre Therapeutics stock forecast page.
SYRE Trading Indicators
How is SYRE performing as a company?
Last year, SYRE revenue was $0.00. In the last five year, SYRE's revenue has gone up by -100% per year. This was slower than the Biotechnology industry average of 30.09%.
Find out more about SYRE's earnings and revenue performance here.
Latest Insiders Trades at SYRE
In the last year, insiders at SYRE have sold more shares than they have bought.
Scott L. Burrows, CFO of SYRE, was the latest SYRE insider to buy. They bought $108,750.00 worth of SYRE shares on Oct 1, 2026.
Get more info about who owns SYRE stock here.
Does SYRE provide a stable income stream?
No, Spyre Therapeutics doesn't provide an income stream by paying out dividends.
Get opinions from other investors
One of the reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to see what other traders have to say.
Step 5: Make your SYRE buy order
You have two main options:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are usually the best for newer investors. - Limit order: A limit order lets you buy or sell a stock at a specific price (or better).
If you want to make sure you're buying or selling at a particular dollar amount limit, place a limit order.
Hit the Open Trade button and eToro will place the order.
If you require more help buying stocks on eToro, click the how to video below:
Step 6: Get notifications regarding your SYRE position
Now that you own some shares in SYRE, you'll want to stay up-to-date on your investment.
Make a watchlist to get notified of the latest news about your SYRE stock.
SYRE Feed
How to Buy Stock in Spyre Therapeutics
To reiterate, here are the 6 steps to buy Spyre Therapeutics stock:
- Choose where to buy Spyre Therapeutics stock
- Open your brokerage account
- Fund your brokerage account
- Analyze Spyre Therapeutics stock
- Make your SYRE buy order
- Get notifications regarding your SYRE position
If you need a brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you would like to keep an eye on your new investment in Spyre Therapeutics, add SYRE to your watchlist by clicking the button below.
Trending Stock Buying Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.